Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Taxanes

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    141 result(s) found for: Taxanes. Displaying page 1 of 8.
    1  2  3  4  5  6  7  8  Next»
    EudraCT Number: 2005-004587-23 Sponsor Protocol Number: UZL/MBC SUBE0501 Start Date*: 2005-12-23
    Sponsor Name:UZ Leuven
    Full Title: A belgian multicenter phase II randomized trial in her2 negative metastatic breast cancer evaluating consolidation antiangiogenic therapy with SU11248 after response to taxane chemotherapy induction
    Medical condition: Patients must meet all of the following inclusion criteria in order to be eligible for participation in this study: • Patients with metastatic breast cancer, histologically proven • Patients receiv...
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2012-005213-39 Sponsor Protocol Number: CJP4.2 Start Date*: 2013-04-10
    Sponsor Name:CENTRE JEAN PERRIN
    Full Title: Phase II pilot study assessing efficacy of a Cisplatine – Métronomic Cyclophosphamide treatment in Patients with Stade IV Triple Negative breast Cancer Secondary Resistant to Anthracyclines and T...
    Medical condition: Triple negative metastatic breast cancer resistant secondary to anthracyclines and taxanes
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-000004-13 Sponsor Protocol Number: ST200-DM-04-005 Start Date*: 2005-09-16
    Sponsor Name:Sigma-Tau i.f.r. S.p.A.
    Full Title: EVALUATION OF ACETYL -L-CARNITINE (ST 200) TO REDUCE INTENSITY OF TAXANES- OR PLATINUM-INDUCED SENSORY NEUROPATHY
    Medical condition: Peripheral neurophaty in cancer patients previously treated with taxanes- or platinum-based chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    7.0 10027655 HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-006669-17 Sponsor Protocol Number: ML061101 Start Date*: 2006-12-27
    Sponsor Name:IST - ISTITUTO NAZIONALE PER LA RICERCA SUL CANCRO
    Full Title: PILOT STUDY OF OXCARBAZEPINE TOLEP ACTIVITY IN ANTICANCER DRUGS NEUROPHATIES
    Medical condition: Neuropathic patients
    Disease: Version SOC Term Classification Code Term Level
    6.1 10034620 PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-000665-35 Sponsor Protocol Number: PM0259CA220B0 Start Date*: 2004-09-08
    Sponsor Name:Pierre Fabre Medicament
    Full Title: Phase II study of oral vinorelbine in combination with capecitabine in metastatic breast cancer patients previously treated with anthracyclines and taxanes
    Medical condition: Treatment in metastatic breast cancer women previously treated with anthracyclines and taxanes
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2011-004712-32 Sponsor Protocol Number: UC-0130/1106 Start Date*: 2012-01-10
    Sponsor Name:UNICANCER
    Full Title: A PHASE II, OPEN-LABEL, MULTICENTER TRIAL OF CABAZITAXEL IN PATIENTS WITH RECURRENT OR METASTATIC HEAD AND NECK CANCER AFTER FAILURE OF CISPLATIN, CETUXIMAB AND TAXANES.
    Medical condition: Recurrent or metastatic head and neck cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067821 Head and neck cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2005-003592-20 Sponsor Protocol Number: D4200C00046 Start Date*: 2005-11-10
    Sponsor Name:AstraZeneca AB
    Full Title: A phase II, double-blind, placebo controlled, randomised study to assess the efficacy and safety of ZD6474 in combination with docetaxel (Taxotere) vs docetaxel alone as 2nd line treatment for adva...
    Medical condition: Advanced breast cancer (ABC)
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Completed) SE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2005-000405-56 Sponsor Protocol Number: GEICAM/2004-06 Start Date*: 2005-06-01
    Sponsor Name:GRUPO ESPAÑOL DE INVETIGACION EN CANCER DE MAMA (GEICAM)
    Full Title: RANDOMIZED CLINICAL TRIAL TO COMPARE THE BENEFIT OF ADDING HERCEPTIN TO CAPECITABINE PLUS VINORELBINE AS SECOND LINE TREATMENT FOR PATIENTS WITH LOCALLY ADVANCED NON OPERABLE OR METASTATIC BREAST ...
    Medical condition: PATIENTS WITH ADVANCED OR METASTATIC BREAST CANCER AND OVEREXPRESSION OF HER2.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-002467-86 Sponsor Protocol Number: FinDoke bi/triweekly Start Date*: 2005-11-10
    Sponsor Name:Liisa Elomaa
    Full Title: A Randomised Multicenter Trial Comparing Docetaxel q2w and Docetaxel q3w in the Treatment of Patients with Metastatic Breast Cancer
    Medical condition: Metastatic Breast Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-005164-83 Sponsor Protocol Number: BR2056 Start Date*: 2006-06-15
    Sponsor Name:Southampton University Hospitals NHS Trust [...]
    1. Southampton University Hospitals NHS Trust
    2. University of Southampton
    Full Title: A PHASE 2 STUDY OF CARBOPLATIN IN COMBINATION WITH GEMCITABINE AS A DOSE DENSE SCHEDULE IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC BREAST CANCER THAT ARE RESISTANT TO ANTHRACYCLINES & TAXANES.
    Medical condition: Metastatic breast cancer
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-000618-38 Sponsor Protocol Number: XRP9881B-3001 Start Date*: 2005-10-24
    Sponsor Name:Aventis Pharmaceuticals Inc.
    Full Title: A randomized, open-label, phase III study of RPR109881 IV every 3 weeks versus capecitabine (Xeloda®) tablets twice daily for 2 weeks in 3-week cycles in patients with metastatic breast cancer prog...
    Medical condition: Metastatic breast cancer patients progressing after taxanes and anthracyclines therapy.
    Disease: Version SOC Term Classification Code Term Level
    10055113
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-002674-12 Sponsor Protocol Number: ATRIO-01/16MAVERICK Start Date*: 2016-11-14
    Sponsor Name:Asociación Terapéutica Investigación Oncológica (ATRIO) [...]
    1. Asociación Terapéutica Investigación Oncológica (ATRIO)
    2. Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunidad Valenciana (FISABIO)
    Full Title: A phase II, randomised, opened and multicenter study, to evaluate the effect of metronomic oral Vinorelbine vs the best treatment of support as maintenance therapy after first-line chemotherapy bas...
    Medical condition: Metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-002084-85 Sponsor Protocol Number: GBG26/TBP (UK sponsor ID-MO05/7222) Start Date*: 2006-06-08
    Sponsor Name:GBG Forschungs GmbH
    Full Title: A multicenter randomized phase III study to compare capecitabine alone or in combination with trastuzumab in patients with HER2 positive metastatic breast cancer and progression after previous trea...
    Medical condition: Patients with HER2 positive metastatic breast cancer and progression after previous treatment with trastuzumab.
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed) SI (Completed) DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2004-000572-14 Sponsor Protocol Number: EFC6088 (XRP9881B/2001) Start Date*: 2004-10-08
    Sponsor Name:Aventis Pharmaceuticals, Inc. (a subsidiary of sanofi-aventis group)
    Full Title: Phase II multicenter, open label, non-randomized study of intravenous RPR109881 q 3 weeks in patients with metastatic breast cancer progressing after therapy with anthracyclines, taxanes, and capec...
    Medical condition: Metastatic breast cancer patients after failure to anthracyclines, taxanes and capecitabine.
    Disease: Version SOC Term Classification Code Term Level
    10055113
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) IT (Completed) ES (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2006-003752-38 Sponsor Protocol Number: om 169 Start Date*: 2003-12-09
    Sponsor Name:OSPEDALE ONCOLOGICO DI BARI
    Full Title: A phase II study of Capecitabine in combination with oral vinorelbine in advanced Breast Cancer
    Medical condition: advancer breast carcinoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006279 Breast neoplasm LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-003582-16 Sponsor Protocol Number: dense get 2005 Start Date*: 2006-07-11
    Sponsor Name:AZIENDA OSPEDALIERA POLICLINICO DI MODENA
    Full Title: Dose-dense treatment with gemcitabine, epirubicin and paclitaxel GET combination in advanced breast cancer a phase II parallel study
    Medical condition: Women with advanced metastatic breast cancer, not previously treated with anthracyclines or taxanes
    Disease: Version SOC Term Classification Code Term Level
    6.1 10006292 HLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2004-005106-79 Sponsor Protocol Number: ST1481-DM02-008 Start Date*: 2005-02-01
    Sponsor Name:Sigma Tau industrie Farmaceutiche Riunite Spa
    Full Title: Phase II study of gimatecan (ST 1481) as salvage treatment in patients with advanced breast cancer after anthracycline /taxanes-based chemotherapy regimen
    Medical condition: advanced breast cancer
    Disease: Version SOC Term Classification Code Term Level
    10006285 LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2022-000435-23 Sponsor Protocol Number: ATX01-22-01-CIPN Start Date*: 2022-07-26
    Sponsor Name:AlgoTherapeutix
    Full Title: A multicenter, randomized, double-blind, parallel group, placebo controlled, Phase 2 study to assess the efficacy and safety of ATX01 (topical amitriptyline hydrochloride 10% and 15% w/w) in compar...
    Medical condition: chemotherapy-induced peripheral neuropathy (CIPN)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004852 10079545 Chemotherapy induced peripheral neuropathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) CZ (Completed) ES (Ongoing) BE (Completed)
    Trial results: View results
    EudraCT Number: 2006-000899-32 Sponsor Protocol Number: EMD72000-031 Start Date*: 2006-07-11
    Sponsor Name:EMD Pharmaceuticals, Inc. (an affiliate of Merck KGaA, Darmstadt, Germany)
    Full Title: Randomized, phase II, open-label controlled study of two different doses and schedules of EMD 72000 (matuzumab) in combination with pemetrexed, or pemetrexed alone, as second-line treatment in subj...
    Medical condition: Stage IIIB/IV non-small cell lung cancer and progressive disease on or after first-line treatment with a platinum analogue in combination with either taxanes, gemcitabine or vinorelbine
    Disease: Version SOC Term Classification Code Term Level
    8.1 10061873 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2005-005669-12 Sponsor Protocol Number: PTK787/ZK 222584 Start Date*: 2006-04-10
    Sponsor Name:AZIENDA OSPEDALIERA S. FILIPPO NERI
    Full Title: A dose-finding study of PTK787/ZK 222584 in combination with weekly vinorelbine and trastuzumab as treatment of patients with metastatic breast cancer overexpressing HER-2/neu pre-treated withy at ...
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    6.1 10038604 SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 12 08:29:25 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA